via University of Birmingham
Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
Learn more: University of Birmingham develops revolutionary eye drops to treat age-related blindness
[osd_subscribe categories=’age-related-macular-degeneration’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “AGE-RELATED MACULAR DEGENERATION’]
The Latest on: Age-related macular degeneration
- Dried goji berries may provide protection against age-related vision loss
Regularly eating a small serving of dried goji berries may provide protection against age-related macular degeneration, the leading cause of vision loss in seniors. The researchers found that 13 ...
- Arizona surgeon first to administer new gene therapy to combat macular degeneration
Dr. Mark Barakat is the first surgeon in the state to administer the new gene therapy for people who suffer from the disease.
- Age-Related Macular Degeneration Market Size, Opportunities, Trends, Products, Revenue Analysis Till 2027
The age-related macular degeneration market is soaring higher all across the globe in recent times. So, the market value is predicted to reach USD 11.18 billion during the forecast period. Over the ...
- Wet Age-Related Macular Degeneration Market to flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight
Market” report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the wet AMD market trends in the 7MM [the United States, EU5 ...
- Age-Related Macular Degeneration Treatment Market Is Predicted To Witness Healthy Growth
Age-Related Macular Degeneration Treatment Market NEW YORK, NY, U.S., May 15, 2022 /EINPresswire.com / -- A report was released recently ...
via Google News and Bing News
